Thank you for your post. Yes, it seems the Philippines is facing a significant resurrgence (not yet as bad as Mar-Apr 2021) but it's moving in that direction. With so many of their hospitals coming under severe pressure, they might re-consider their options and we'll see the weathier and well-connected mysteriously getting LL.
This could also lead to some other interesting outcomes. It's just very distressing rising deaths might become the catalyst to trigger Leronlimab's usage rather than intelligent action by our misguided FDA.
Market Data 
Markets 
AI
